FrancophonIA/ELRC3.0 huggingface dataset:
English: The box contains 7, 14, 28, 30 or 84 (multipack containing 3 packs of 28) transdermal patches, individually sealed in sachets.
Spanish: Cada caja contiene 7, 14, 28, 30 u 84 (envase múltiple que contiene 3 cajas de 28) parches transdérmicos sellados individualmente en sobres.
English: Warnings and precautions Talk to your doctor or pharmacist before using Neupro.
Spanish: Advertencias y precauciones Consulte a su médico o farmacéutico antes de empezar a usar Neupro, ya que:
English: Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 748 Neupro- and 214 placebo-treated patients, 65.5% of the patients on Neupro and 33.2% of patients on placebo reported at least one adverse reaction.
Spanish: A partir del análisis conjunto de los ensayos clínicos controlados con placebo, en los que se incluyeron un total de 748 pacientes tratados con Neupro y 214 pacientes tratados con placebo, se calculó que el 65,5% de los pacientes tratados con Neupro y el 33,2% de los pacientes tratados con placebo presentaron al menos una reacción adversa.
English: How to use the Neupro patches
Spanish: Cómo usar los parches de Neupro
English: How to use Neupro
Spanish: Cómo usar Neupro
English: What Neupro is used for
Spanish: Para qué se utiliza Neupro
English: hypersexuality, libido increased), confusional state, disorientationd, agitationd
Spanish: (incluyendo hipersexualidad, aumento de la libido), estado de confusión, desorientación d,
English: The strengths are 1 mg/24 h, 2 mg/24 h, 3 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h. The patches of 1 mg/24 h and 3 mg/24 h are used for the treatment of Restless Leg Syndrome, while the patches of 4 mg/24 h, 6 mg/24 h and 8 mg/24 h are used for the treatment of Parkinson's disease.
Spanish: Las dosis son 1 mg/24 h, 2 mg/24 h, 3 mg/24 h, 4 mg/24 h, 6 mg/24 h y 8 mg/24 h. Los parches de 1 mg/24 h y 3 mg/24 h se utilizan en el tratamiento del Síndrome de Piernas Inquietas, mientras que los parches de 4 mg/24 h, 6 mg/24 h y 8 mg/24 h se usan para el tratamiento de la enfermedad de
English: Palpitationse, atrial fibrillatione, supraventricular tachycardia e
Spanish: fibrilación auricular e, taquicardia supraventricular e
English: Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro transdermal patch are nausea, vomiting, application site reactions, somnolence, dizziness and headache.
Spanish: Las reacciones adversas (RA) descritas en más del 10% de los pacientes tratados con Neupro parche transdérmico son náuseas, vómitos, reacciones en el lugar de aplicación, somnolencia, mareos y cefalea.
English: The strengths are 1 mg/24 h, 2 mg/24 h and 3 mg/24 h for the treatment of Restless Leg Syndrome.
Spanish: Las dosis son 1 mg/24 h, 2 mg/24 h y 3 mg/24 h para el tratamiento del Síndrome de Piernas Inquietas.
English: • movements you cannot control related to Parkinson's disease (dyskinesia)
Spanish: • movimientos involuntarios relacionados la enfermedad de Parkinson (discinesia)
English: Boxes containing 7, 14, 28, 30 or 84 (multipack containing 3 packs of 28) patches, which are individually sealed in sachets.
Spanish: Envases que contienen 7, 14, 28, 30 u 84 (envase múltiple que contiene 3 envases de 28) parches, cada parche está incluido en un sobre individual.
English: • Do not stick Neupro on the same area of skin twice within 14 days.
Spanish: • No coloque el parche de Neupro en la misma zona de la piel hasta que hayan pasado 14 días desde que se lo colocara en ese mismo sitio.
English: Observed in studies performed in patients with Parkinson's disease Parkinson's disease
Spanish: Observado en estudios realizados en pacientes con Enfermedad de Parkinson
English: • binge eating (eating large amounts of food in a short period of time) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).
Spanish: • episodios de atracón (comer grandes cantidades de comida en un corto periodo de tiempo) o comer compulsivamente (comer más comida de lo normal o más de la que se necesita para satisfacer su apetito).
English: Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro are nausea, application site reactions, asthenic conditions and headache.
Spanish: Las reacciones adversas (RA) descritas en más del 10% de los pacientes tratados con Neupro son náuseas, reacciones en el lugar de aplicación, problemas de astenia y cefalea.
English: Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,307 Neuproand 607 placebo-treated patients, 72.5% of the patients on Neupro and 58.0% of patients on placebo reported at least one adverse reaction.
Spanish: A partir del análisis conjunto de los ensayos clínicos controlados con placebo, en los que se incluyeron 1.307 pacientes tratados con Neupro y 607 tratados con placebo, se calculó que el 72,5% de los pacientes tratados con Neupro y el 58,0% de los tratados con placebo presentaron al menos una reacción adversa.
English: These symptoms are either reduced or their duration is shortened with Neupro treatment.
Spanish: Si estos síntomas aparecen se debe reducir la dosis o interrumpir el tratamiento gradualmente.
English: Dopamine dysregulation syndromec, perception disturbancese
Spanish: Síndrome de disregulación dopaminérgica c, alteraciones de la percepción e
English: CGI-I responder rates (much improved, very much improved) were 43.0% and 67.5% for placebo and rotigotine respectively (difference 24.5% CI 95%: 14.2%; 34.8%, p<0.0001).
Spanish: Impresión Globlal Clínica de mejoría (mejoradas, muy mejoradas) fueron 43,0% y 67,5% para placebo y rotigotina respectivamente (diferencia del 24,5% IC95%: 14,2%; 34,8%, p<0,0001).
English: Observed in 2011 data pool of double-blind placebo-controlled studies e
Spanish: Observado en la base de datos de estudios doble ciego controlados con placebo en2011
English: • For doses higher than 8 mg/24 h (doses prescribed by your doctor above the available strengths),
Spanish: • Para dosis superiores a 8 mg/24 h (dosis prescritas por su médico por encima de las dosis disponibles), se deben usar varios parches para alcanzar la dosis final.
English: At the beginning of the fourth week, you should take Neupro 8 mg (package marked with “Week 4”).
Spanish: Al comienzo de la cuarta semana debería usar Neupro 8 mg (envase marcado con “Semana 4”).
English: Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, Povidone K90,
Spanish: Poli (dimetilsiloxano, trimetilsilil silicato) copolimerizado, Povidona K90,
English: For example, a daily dose of 14 mg can be reached by applying one patch of 6 mg/24 h and one patch of 8 mg/24 h and likewise, a daily dose of 16 mg can be reached by applying two patches of 8 mg/24 h.
Spanish: Por ejemplo, la dosis diaria de 14 mg se alcanza usando un parche de 6 mg/24 h y un parche de 8 mg/24 h o viceversa, la dosis de 16 mg se alcanza usando dos parches de 8 mg/24 h.
English: At the beginning of the third week, you should take Neupro 6 mg (package marked with “Week 3”).
Spanish: Al comienzo de la tercera semana debería usar Neupro 6 mg (envase marcado con “Semana 3”).
English: Psychotic disorder, obsessivecompulsive disorder, aggressive behaviour/ aggressionb, delusiond, deliriumd
Spanish: Trastorno psicótico, trastorno obsesivo compulsivo, comportamiento agresivo/ agresión b, alucinaciones d,
English: What Neupro is Neupro contains the active substance rotigotine.
Spanish: Neupro contiene el principio activo rotigotina.
English: Other medicines and Neupro
Spanish: Uso de Neupro con otros medicamentos
English: What Neupro contains The active substance is rotigotine.
Spanish: Composición de Neupro El principio activo es rotigotina.
English: At the beginning of the second week, you should take Neupro 4 mg (package marked with “Week 2”).
Spanish: Al comienzo de la segunda semana debería usar Neupro 4 mg (envase marcado con “Semana 2”).
English: paranoia e, confusional state e, psychotic disorder e, delusione, deliriume
Spanish: paranoia e, estado de confusión e,
English: The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of Neupro in 7.2% of subjects.
Spanish: La mayoría de las reacciones en el lugar de aplicación fueron leves o moderadas y limitadas a las zonas de aplicación.
English: AST, ALT, GGT), weight increased, heart rate increased, CPK increasedd
Spanish: GGT, GPT y GOT), aumento de peso, aumento de la frecuencia cardiaca, aumento de CPK
English: At the end of maintenance, the mean UPDRS part III score had improved by 7.0 points in rotigotine-treated patients (baseline 29.6), and by 3.9 points in the placebo group (baseline 32.0).
Spanish: Al final de la fase de mantenimiento los pacientes tratados con rotigotina tuvieron una mejoría en la puntuación media en la escala UPDRS (parte III) de 7,0 puntos (inicial 29,6 puntos) y de 3,9 puntos en el grupo placebo (inicial 32,0 puntos).
English: In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions.
Spanish: En los ensayos en los que se rotó el lugar de aplicación, tal como se indica en las instrucciones incluidas en la ficha técnica y en el prospecto del envase, el 34,2% de los 748 pacientes que usaron Neupro presentó reacciones en el lugar de aplicación.
English: Dosing in patients with early-stage Parkinson's disease:
Spanish: Posología en pacientes con enfermedad de Parkinson en etapas iniciales:
English: If application site reactions occur which last for more than a few days or are persistent, if there is an increase in severity, or if the skin reaction spreads outside the application site, an assessment of the risk/benefit balance for the individual patient should be conducted.
Spanish: Se debe realizar un estudio del balance riesgo-beneficio de la administración de Neupro al paciente en los siguientes casos: si aparecen reacciones en el lugar de aplicación que duren más de varios días o que sean persistentes; si aumenta la intensidad de las reacciones o si la reacción cutánea se extiende fuera del lugar de aplicación.
English: For most patients with early stage Parkinson's disease, the right dose is reached within 3 or 4 weeks, at doses of 6 mg per day or 8 mg per day, respectively.
Spanish: En la mayoría de los casos de enfermedad de Parkinson en etapas iniciales, la dosis apropiada se alcanza en 3 o 4 semanas, con dosis de 6 mg/24 h u 8 mg/24 h, respectivamente.
English: If you stop using Neupro
Spanish: Si interrumpe el tratamiento con Neupro
English: In trials where the application sites were rotated as reflected in the instructions provided in SmPC and package leaflet, 35.7% of 830 patients using the Neupro transdermal patch, experienced application site reactions.
Spanish: En los ensayos en los que se rotó el lugar de aplicación como se indica en las instrucciones incluidas en la ficha técnica y en el prospecto del envase, el 35,7% de los 830 pacientes que usaron Neupro parche transdérmico presentó reacciones en el lugar de aplicación.
English: Each patch of 30 cm2 contains 13.5 mg of rotigotine.
Spanish: Cada parche de 30 cm2 contiene 13,5 mg de rotigotina.
English: The outside is tan-coloured and is imprinted with Neupro 1 mg/24 h or 3 mg/24 h.
Spanish: La parte exterior es de color tostado y lleva impresa la leyenda Neupro 1 mg/24 h o 3 mg/24 h.
English: Sleep attacks/sudden onset of sleep, sexual desire disordersa (incl.
Spanish: Ataques de sueño/episodios de sueño repentino, trastornos del deseo sexual a
English: erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity), asthenic conditions a
Spanish: (incluyendo eritema, prurito, irritación, erupción, dermatitis, vesículas, dolor, eczema, inflamación, hinchazón, decoloración, pápulas, excoriacione s, urticaria, hipersensibili dad), problemas de astenia a
English: syncope, syncope vasovagal, loss of consciousness), dyskinesiae, dizziness posturale, lethargye, convulsione
Spanish: (incluyendo síncope, síncope vasovagal, pérdida de consciencia), discinesia, mareos posturales, letargo
English: The outside is tan-coloured and is imprinted with Neupro 4 mg/24 h, Neupro 6 mg/24 h or Neupro 8 mg/ 24 h.
Spanish: La parte exterior es de color tostado y lleva impresa la leyenda Neupro 4 mg/24 h, Neupro 6 mg/24 h o Neupro 8 mg/24 h.
English: • 8 mg/24 h: Each patch releases 8 mg of rotigotine per 24 hours.
Spanish: • 8 mg/24 h: Un parche libera 8 mg de rotigotina cada 24 horas.
English: Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h Transdermal patch
Spanish: Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h Parche transdérmico
English: 7 transdermal patches of Neupro 6 mg/24 h
Spanish: 7 parches transdérmicos de Neupro 6 mg/24 h
English: 7 transdermal patches of Neupro 8 mg/24 h
Spanish: 7 parches transdérmicos de Neupro 8 mg/24 h
English: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h'.
Spanish: La parte exterior de la capa cobertora es de color tostado y lleva impresa la leyenda ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h u 8 mg/24 h'.
English: Each patch of 40 cm2 contains 18.0 mg of rotigotine.
Spanish: Cada parche de 40 cm2 contiene 18,0 mg de rotigotina.
English: If any of the above apply to you, do not use Neupro.
Spanish: No use Neupro si le ocurre alguna de las opciones anteriores.
English: Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch
Spanish: Neupro 1 mg/24 h parche transdérmico Neupro 3 mg/24 h parche transdérmico
English: Each patch of 10 cm2 contains 4.5 mg of rotigotine.
Spanish: Cada parche de 10 cm2 contiene 4,5 mg de rotigotina.
English: Each patch of 20 cm2 contains 9.0 mg of rotigotine.
Spanish: Cada parche de 20 cm2 contiene 9,0 mg de rotigotina.
English: Dopamine dysregulation syndromec
Spanish: Síndrome de disregulación dopaminérgica c
English: • Restless Legs Syndrome (RLS) - this can be associated with discomfort in your legs or arms,
Spanish: • Síndrome de Piernas Inquietas (SPI) - este síndrome puede asociarse con molestias en las piernas o en los brazos, necesidad de moverse, alteraciones del sueño y sensación de cansancio o sueño durante el día.
English: 7 transdermal patches of Neupro 4 mg/24 h
Spanish: 7 parches transdérmicos de Neupro 4 mg/24 h
English: Neupro 4 mg/24 h transdermal patch Each patch releases 4 mg of rotigotine per 24 hours.
Spanish: Neupro 4 mg/24 h parche transdérmico Un parche libera 4 mg de rotigotina cada 24 horas.
English: How to store Neupro
Spanish: Conservación de Neupro
English: The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h.
Spanish: La parte exterior es de color tostado y lleva impresa la leyenda Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h u 8 mg/24 h.
English: The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h.
Spanish: La parte exterior es de color tostado y lleva impresa la leyenda Neupro 2 mg/24 h.
English: syncope, syncope vasovagal, loss of consciousness), dyskinesia, dizziness postural, lethargy
Spanish: (incluyendo síncope, síncope vasovagal, pérdida de la consciencia), disquinesia e, mareo postural e,
English: pathological gambling, stereotypy/ punding, binge eating/eating disorder b, compulsive shopping c)
Spanish: (incluyendo ludopatía, estereotipia/acto s compulsivos como el jugueteo, episodios de atracón/ trastornos de la alimentación b,
English: Neupro 1 mg/24 h transdermal patch EU/1/05/331/038
Spanish: Neupro 1 mg/24 h parche transdérmico EU/1/05/331/038
English: Perception disturbancesa
Spanish: Trastornos compulsivos
English: Neupro 6 mg/24 h transdermal patch EU/1/05/331/007
Spanish: Neupro 6 mg/24 h parche transdérmico EU/1/05/331/007
English: Neupro 8 mg/24 h transdermal patch EU/1/05/331/010
Spanish: Neupro 8 mg/24 h parche transdérmico EU/1/05/331/010
English: Neupro 4 mg/24 h transdermal patch EU/1/05/331/004
Spanish: Neupro 4 mg/24 h parche transdérmico EU/1/05/331/004
English: Neupro 3 mg/24 h transdermal patch EU/1/05/331/047
Spanish: Neupro 3 mg/24 h parche transdérmico EU/1/05/331/047
English: Neupro 4 mg/24 h transdermal patch Neupro 6 mg/24 h transdermal patch Neupro 8 mg/24 h transdermal patch
Spanish: Neupro 4 mg/24 h parche transdérmico Neupro 6 mg/24 h parche transdérmico Neupro 8 mg/24 h parche transdérmico
English: EU/1/05/331/047 [7 transdermal patches] EU/1/05/331/049 [28 transdermal patches] EU/1/05/331/050 [30 transdermal patches] EU/1/05/331/058 [14 transdermal patches]
Spanish: EU/1/05/331/047 [7 parches transdérmicos] EU/1/05/331/049 [28 parches transdérmicos] EU/1/05/331/050 [30 parches transdérmicos] EU/1/05/331/058 [14 parches transdérmicos]
English: • 4 mg/24 h: Each patch releases 4 mg of rotigotine per 24 hours.
Spanish: • 4 mg/24 h: Un parche libera 4 mg de rotigotina cada 24 horas.
English: • Stick the Neupro patch onto your skin as soon as you have opened the sachet and removed the release liner.
Spanish: • Doble el parche por la mitad hasta que se abra la línea en S de la capa desechable.
English: EU/1/05/331/038 [7 transdermal patches] EU/1/05/331/040 [28 transdermal patches] EU/1/05/331/041 [30 transdermal patches] EU/1/05/331/056 [14 transdermal patches]
Spanish: EU/1/05/331/038 [7 parches transdérmicos] EU/1/05/331/040 [28 parches transdérmicos] EU/1/05/331/041 [30 parches transdérmicos] EU/1/05/331/056 [14 parches transdérmicos]
English: EU/1/05/331/010 [7 transdermal patches] EU/1/05/331/011 [28 transdermal patches] EU/1/05/331/033 [30 transdermal patches] EU/1/05/331/061 [14 transdermal patches]
Spanish: EU/1/05/331/010 [7 parches transdérmicos] EU/1/05/331/011 [28 parches transdérmicos] EU/1/05/331/033 [30 parches transdérmicos] EU/1/05/331/061 [14 parches transdérmicos]
English: The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of treatment with Neupro in only 4.3% of all subjects receiving Neupro.
Spanish: Las reacciones en el lugar de aplicación produjeron la interrupción del tratamiento en el 4,3% de los pacientes.
English: If a generalised skin reaction (e.g. allergic rash, including erythematous, macular, papular rash or pruritus) associated with the use of Neupro is observed, Neupro should be discontinued.
Spanish: Se debe interrumpir el tratamiento con Neupro si se observa una reacción cutánea generalizada asociada al uso de este medicamento (p. ej., exantema alérgico de tipo eritematoso, macular o papular o prurito).
English: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 1 mg/24 h'.
Spanish: La parte exterior de la capa cobertora es de color tostado y lleva impresa la leyenda ‘Neupro 1 mg/24 h'.
English: Neupro 8 mg/24 h transdermal patch rotigotine
Spanish: Neupro 8 mg/24 h parche transdérmico rotigotina
English: Neupro 1 mg/24 h transdermal patch Each patch releases 1 mg of rotigotine per 24 hours.
Spanish: Neupro 2 mg/24 h parche transdérmico Un parche libera 2 mg de rotigotina cada 24 horas.
English: Neupro 1 mg/24 h transdermal patch rotigotine
Spanish: Neupro 1 mg/24 h parche transdérmico rotigotina
English: Neupro 8 mg/24 h transdermal patch
Spanish: Neupro 8 mg/24 h parche transdérmico
English: EU/1/05/331/004 [7 transdermal patches] EU/1/05/331/005 [28 transdermal patches] EU/1/05/331/021 [30 transdermal patches] EU/1/05/331/059 [14 transdermal patches]
Spanish: EU/1/05/331/004 [7 parches transdérmicos] EU/1/05/331/005 [28 parches transdérmicos] EU/1/05/331/021 [30 parches transdérmicos] EU/1/05/331/059 [14 parches transdérmicos]
English: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h'.
Spanish: La parte exterior de la capa cobertora es de color tostado y lleva impresa la leyenda ‘Neupro 2 mg/24 h'.
English: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 3 mg/24 h'.
Spanish: La parte exterior de la capa cobertora es de color tostado y lleva impresa la leyenda ‘Neupro 3 mg/24 h'.
English: Neupro 6 mg/24 h transdermal patch rotigotine
Spanish: Neupro 6 mg/24 h parche transdérmico rotigotina
English: EU/1/05/331/007 [7 transdermal patches] EU/1/05/331/008 [28 transdermal patches] EU/1/05/331/027 [30 transdermal patches] EU/1/05/331/060 [14 transdermal patches]
Spanish: EU/1/05/331/007 [7 parches transdérmicos] EU/1/05/331/008 [28 parches transdérmicos] EU/1/05/331/027 [30 parches transdérmicos] EU/1/05/331/060 [14 parches transdérmicos]
English: Neupro 6 mg/24 h transdermal patch
Spanish: Neupro 6 mg/24 h parche transdérmico
English: EU/1/05/331/001 [7 transdermal patches] EU/1/05/331/002 [28 transdermal patches] EU/1/05/331/015 [30 transdermal patches] EU/1/05/331/057 [14 transdermal patches]
Spanish: EU/1/05/331/001 [7 parches transdérmicos] EU/1/05/331/002 [28 parches transdérmicos] EU/1/05/331/015 [30 parches transdérmicos] EU/1/05/331/057 [14 parches transdérmicos]
English: These are usually mild or moderate in intensity and transient even if treatment is continued.
Spanish: Al inicio del tratamiento pueden presentarse reacciones adversas dopaminérgicas como náuseas y vómitos, que suelen ser leves o moderadas y transitorias, aunque continúe el tratamiento.
English: Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Spanish: El tratamiento con Neupro reduce o disminuye la duración de estos síntomas.
English: Neupro 4 mg/24 h transdermal patch
Spanish: Neupro 4 mg/24 h parche transdérmico
English: Application and instillation site reactionsa (incl.
Spanish: Reacciones en el lugar de aplicación e instilación a
English: Constipatione, dry mouthe, abdominal paine, diarrhoeac
Spanish: sequedad de boca e, dolor abdominal e,
English: EU/1/05/331/018 [84 transdermal patches (3 packs of 28)]
Spanish: EU/1/05/331/018 [84 parches transdérmicos (3 cajas de 28)]
English: EU/1/05/331/036 [84 transdermal patches (3 packs of 28)]
Spanish: EU/1/05/331/036 [84 parches transdérmicos (3 cajas de 28)]
English: EU/1/05/331/024 [84 transdermal patches (3 packs of 28)]
Spanish: EU/1/05/331/024 [84 parches transdérmicos (3 cajas de 28)]
English: EU/1/05/331/044 [84 transdermal patches (3 packs of 28)]
Spanish: EU/1/05/331/044 [84 parches transdérmicos (3 cajas de 28)]
English: EU/1/05/331/053 [84 transdermal patches (3 packs of 28)]
Spanish: EU/1/05/331/053 [84 parches transdérmicos (3 cajas de 28)]
English: EU/1/05/331/030 [84 transdermal patches (3 packs of 28)]
Spanish: EU/1/05/331/030 [84 parches transdérmicos (3 cajas de 28)]
English: Erythema e, hyperhidrosise, pruritus generalisede, skin irritatione, dermatitis contacte, rash generalisede
Spanish: irritación cutánea e, dermatitis de contacto e, erupción generalizada e
English: Oedema peripheral, asthenic conditionsa (incl.
Spanish: Edema periférico, problemas de astenia a
English: Neupro 4 mg/24 h transdermal patch Rotigotine
Spanish: Neupro 4 mg/24 h parche transdérmico rotigotina
English: Neupro 2 mg/24 h transdermal patch Rotigotine
Spanish: Neupro 2 mg/24 h parche transdérmico Rotigotina
English: Neupro 2 mg/24 h transdermal patch rotigotine
Spanish: Neupro 2 mg/24 h parche transdérmico rotigotina
English: Neupro 3 mg/24 h transdermal patch rotigotine
Spanish: Neupro 3 mg/24 h parche transdérmico rotigotina
English: What Neupro contains
Spanish: Qué es Neupro
English: Weight decreased e, hepatic enzyme increasede (incl.
Spanish: aumento de enzimas hepáticas e
English: Restless Legs Syndrome
Spanish: Síndrome de Piernas inquietas
English: Other information about Clopidogrel Teva:
Spanish: Otras informaciones sobre Clopidogrel Teva:
English: It is available as pink tablets (75 mg).
Spanish: y se presenta en forma de comprimidos de color rosa (75 mg).
English: Clopidogrel Teva clopidogrel EPAR summary for the public
Spanish: Clopidrogel Teva clopidogrel Resumen del EPAR para el público general
English: The full EPAR for Clopidogrel Teva can be found here.
Spanish: El texto completo del EPAR de Clopidogrel Teva puede encontrarse aquí.